Recently,Salubris announced that the clinical trial application for its independently developed innovative drug SAL0167 tablets(project code:SAL0167)has been approved,allowing the initiation of clinical trials for the treatment of hyperlipidemia[1].
SAL0167 is a cyclic peptide drug independently designed by the company with proprietary intellectual property rights.Cyclic peptides exhibit high affinity and specificity for their targets;therefore,for patients with hypercholesterolemia requiring potent lipid-lowering therapy,SAL0167 holds the potential to become a preferred treatment option.
If successfully developed and approved for marketing,SAL0167 is expected to offer a new therapeutic option for a broader patient population,address unmet clinical needs,and further enrich the company’s innovative product pipeline in the chronic disease area of cardiovascular-kidney-metabolic (CKM) syndrome.
About Cyclic Peptides[2-3]
Cyclic peptide drugs represent a novel therapeutic modality that bridges the gap between small-molecule drugs and antibody biologics.They combine the key advantages of both classes:retaining the high potency,high selectivity,and favorable safety profile of antibodies,while also offering the low production cost,excellent stability,and oral bioavailability characteristic of small molecules.These unique attributes position cyclic peptides a significant breakthrough and promising direction in contemporary drug discovery and development.
References：
[1]Shenzhen Salubris Pharmaceuticals Co.,Ltd.–Announcement regarding the Clinical Trial Approval Notification for SAL0167.
[2]Gang D,Kim DW,Park H-S.Cyclic Peptides:Promising Scaffolds for Biopharmaceuticals.Genes.2018;9(11):557.
[3]Atangcho L,Navaratna T,Thurber GM.Hitting Undruggable Targets:Viewing Stabilized Peptide Development through the Lens of Quantitative Systems Pharmacology.Trends in Biochemical Sciences.2018;44,241-257.
Disclaimer:
1.This material is intended solely to provide knowledge about the disease area and increase disease awareness.It is not for promotional purposes.
2.The information contained in this material is for reference only.Please follow the advice or guidance of a physician or other healthcare professional.
|About Salubris
Salubris is an innovative,international pharmaceutical company that integrates R&D,manufacturing,and sales.We remain committed to the mission of"providing excellent pharmaceutical products for human health"and focus on the chronic disease area of cardiovascular-kidney-metabolic(CKM) syndrome,safeguarding life and health.Our marketed novel drugs include Xinlitan®(for hypertension),XinchaoTuo®(for hypertension),Fulitan®and Fuli'an®(for hypertension),Ennaluo® (for renal anemia),and Xinliting®(for type 2 diabetes mellitus).
Globally,Salubris has established five innovative drug R&D centers and three medical device R&D bases.It has also built innovation platforms covering small molecules,peptides/cyclic peptides,antibody-based biologics,siRNA oligonucleotides,in vivo gene editing,AIDD(AI-driven drug discovery),and medical devices,all aimed at addressing unmet clinical needs.
